Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc.

All antitrust approvals required to close the transaction received.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news